Sam Chun Dang Pharm (KOSDAQ:000250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 27
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Pharma Industry Analysis
UpdatedMar 28, 2026
DataAggregated Company Financials
Companies106
- 7D6.0%
- 3M34.7%
- 1Y77.7%
- YTD33.1%
In the last week, the Pharma industry is up 6.0%, with Sam Chun Dang Pharm up 22%. Meanwhile, Caregen actually underperformed within the industry, shrinking 13% in the last week. This means that the industry has gained 78% over the past year. Earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the South Korean Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 28 Mar 2026 | ₩93.8t | ₩31.9t | ₩1.6t | 14.4x | 60.4x | 2.9x |
| Mon, 23 Feb 2026 | ₩90.5t | ₩31.4t | ₩1.2t | 16.4x | 76.4x | 2.9x |
| Wed, 21 Jan 2026 | ₩70.8t | ₩31.4t | ₩1.2t | 16x | 59.8x | 2.3x |
| Fri, 19 Dec 2025 | ₩70.7t | ₩31.4t | ₩1.2t | 17.2x | 59.7x | 2.2x |
| Sun, 16 Nov 2025 | ₩70.3t | ₩31.3t | ₩1.0t | 18.9x | 68.6x | 2.2x |
| Tue, 14 Oct 2025 | ₩63.3t | ₩31.3t | ₩1.0t | 19.8x | 63x | 2x |
| Thu, 11 Sep 2025 | ₩61.8t | ₩31.1t | ₩925.9b | 19.8x | 66.7x | 2x |
| Sat, 09 Aug 2025 | ₩57.7t | ₩30.6t | ₩909.7b | 18.6x | 63.4x | 1.9x |
| Mon, 07 Jul 2025 | ₩54.5t | ₩30.2t | ₩914.7b | 16.3x | 59.6x | 1.8x |
| Wed, 04 Jun 2025 | ₩53.8t | ₩29.9t | ₩880.1b | 17x | 61.2x | 1.8x |
| Fri, 02 May 2025 | ₩53.4t | ₩29.6t | ₩984.4b | 17.6x | 54.2x | 1.8x |
| Sun, 30 Mar 2025 | ₩51.9t | ₩29.7t | ₩916.2b | 16.1x | 56.6x | 1.7x |
| Tue, 25 Feb 2025 | ₩55.9t | ₩29.5t | ₩1.0t | 12.1x | 55.7x | 1.9x |
| Thu, 23 Jan 2025 | ₩55.9t | ₩29.6t | ₩1.0t | 12.3x | 55.1x | 1.9x |
| Sat, 21 Dec 2024 | ₩51.7t | ₩29.4t | ₩989.8b | 12.7x | 52.2x | 1.8x |
| Mon, 18 Nov 2024 | ₩53.0t | ₩28.8t | ₩853.3b | 14.6x | 62.2x | 1.8x |
| Wed, 16 Oct 2024 | ₩64.0t | ₩28.7t | ₩833.2b | 15.8x | 76.8x | 2.2x |
| Fri, 13 Sep 2024 | ₩56.6t | ₩28.8t | ₩836.8b | 15x | 67.6x | 2x |
| Sun, 11 Aug 2024 | ₩54.2t | ₩28.5t | ₩768.0b | 14.8x | 70.5x | 1.9x |
| Tue, 09 Jul 2024 | ₩53.4t | ₩28.4t | ₩762.2b | 13.5x | 70.1x | 1.9x |
| Thu, 06 Jun 2024 | ₩53.8t | ₩30.2t | ₩909.1b | 13.4x | 59.2x | 1.8x |
| Sat, 04 May 2024 | ₩53.9t | ₩29.7t | ₩942.4b | 17.4x | 57.2x | 1.8x |
| Mon, 01 Apr 2024 | ₩55.4t | ₩29.4t | ₩922.9b | 17.7x | 60.1x | 1.9x |
| Wed, 28 Feb 2024 | ₩53.2t | ₩29.6t | ₩593.1b | 19.9x | 89.7x | 1.8x |
| Fri, 26 Jan 2024 | ₩51.3t | ₩29.6t | ₩592.3b | 22.3x | 86.6x | 1.7x |
| Sun, 24 Dec 2023 | ₩52.3t | ₩29.6t | ₩588.2b | 21.7x | 88.9x | 1.8x |
| Tue, 21 Nov 2023 | ₩49.2t | ₩29.4t | ₩681.2b | 16.7x | 72.2x | 1.7x |
| Thu, 19 Oct 2023 | ₩46.8t | ₩29.3t | ₩683.3b | 16.8x | 68.5x | 1.6x |
| Sat, 16 Sep 2023 | ₩52.9t | ₩29.3t | ₩683.3b | 17.1x | 77.4x | 1.8x |
| Mon, 14 Aug 2023 | ₩53.7t | ₩28.8t | ₩899.2b | 23.1x | 59.8x | 1.9x |
| Wed, 12 Jul 2023 | ₩44.9t | ₩28.8t | ₩899.2b | 19.3x | 49.9x | 1.6x |
| Fri, 09 Jun 2023 | ₩48.2t | ₩28.9t | ₩908.1b | 22.6x | 53x | 1.7x |
| Sun, 07 May 2023 | ₩48.6t | ₩28.5t | ₩602.7b | 21.3x | 80.7x | 1.7x |
| Tue, 04 Apr 2023 | ₩44.7t | ₩28.5t | ₩602.8b | 19x | 74.1x | 1.6x |
Price to Earnings Ratio
74.1x
Current Industry PE
- Investors are pessimistic on the South Korean Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 60.4x which is lower than its 3-year average PE of 65.7x.
- The 3-year average PS ratio of 1.9x is lower than the industry's current PS ratio of 2.9x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 37% per year over the last three years.
- Revenues for these companies have grown 3.9% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | -5.47% | |
| Healthcare | 1.79% | |
| Pharma | 5.99% | |
| Pharma | 5.99% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A000250 Sam Chun Dang Pharm | ₩1.11m | 22.5% +₩4.7t | 557.4% | PE4910.8x | |
| A003000 Bukwang Pharmaceutical | ₩9.60k | 60.3% +₩356.2b | 146.2% | PE75.4x | |
| A009420 Hanall Biopharma | ₩63.30k | 12.0% +₩345.3b | 123.7% | PS20.7x | |
| A140410 Mezzion PharmaLtd | ₩98.00k | 7.0% +₩194.4b | 219.7% | PS376.4x | |
| A237690 ST PharmLtd | ₩159.30k | 5.6% +₩176.9b | 115.0% | PE60.3x |
